Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Neon Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Neon Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Neon Therapeutics Raises Additional USD36 Million in Series B Financing 13
Neon Therapeutics Raises USD70 Million in Series B Financing 15
Neon Therapeutics Raises USD55 Million in Series A Venture Financing 17
Partnerships 18
Natera Enters into Research Agreement with Neon Therapeutics 18
Neon Therapeutics Enters into Agreement with Merck 19
Neon Therapeutics Enters into Agreement with Apexigen 20
CRISPR Therapeutics and Neon Therapeutics Enter into Research Agreement 21
Vedantra Pharma Extends Research Agreement with Neon Therapeutics 22
Neon Therapeutics Enters into Research Agreement with Netherlands Cancer Institute 23
Neon Therapeutics Enters into Agreement with Bristol-Myers Squibb 24
Licensing Agreements 25
Neon Therapeutics Enters into Licensing Agreement with Netherlands Cancer Institute 25
Neon Therapeutics Enters into Licensing Agreement with Sanquin Blood Supply Foundation 26
Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 27
Equity Offering 28
Neon Therapeutics Raises USD100 Million in IPO of Shares 28
Neon Therapeutics Inc – Key Competitors 30
Neon Therapeutics Inc – Key Employees 31
Neon Therapeutics Inc – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Aug 06, 2018: Neon Therapeutics reports second quarter 2018 financial results and recent business highlights 33
Corporate Communications 35
Dec 12, 2017: Neon Therapeutics Expands Board of Directors with Leading Experts in Cancer Drug Discovery and Corporate Finance 35
Jun 16, 2017: Dr. Yasir Al-Wakeel Joins Neon Therapeutics as Chief Financial Officer 36
Product News 37
Jul 05, 2017: Initial Results from Dana-Farber Cancer Institute Personalized Neoantigen Vaccine Published in Nature 37
07/05/2017: Personal neoantigen vaccine prompts strong anti-tumor response in patients, study showsx 38
Feb 21, 2017: Using Mono-Allelic Mass Spectrometry Data to Improve Epitope Prediction Algorithms Published in Immunity 40
Clinical Trials 41
May 08, 2018: Neon Therapeutics Announces First Patient Treated in Clinical Trial Evaluating Personal Cancer Vaccine NEO-PV-01 in Combination with KEYTRUDA (pembrolizumab) and Chemotherapy 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Neon Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Neon Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Neon Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Neon Therapeutics Raises Additional USD36 Million in Series B Financing 13
Neon Therapeutics Raises USD70 Million in Series B Financing 15
Neon Therapeutics Raises USD55 Million in Series A Venture Financing 17
Natera Enters into Research Agreement with Neon Therapeutics 18
Neon Therapeutics Enters into Agreement with Merck 19
Neon Therapeutics Enters into Agreement with Apexigen 20
CRISPR Therapeutics and Neon Therapeutics Enter into Research Agreement 21
Vedantra Pharma Extends Research Agreement with Neon Therapeutics 22
Neon Therapeutics Enters into Research Agreement with Netherlands Cancer Institute 23
Neon Therapeutics Enters into Agreement with Bristol-Myers Squibb 24
Neon Therapeutics Enters into Licensing Agreement with Netherlands Cancer Institute 25
Neon Therapeutics Enters into Licensing Agreement with Sanquin Blood Supply Foundation 26
Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 27
Neon Therapeutics Raises USD100 Million in IPO of Shares 28
Neon Therapeutics Inc, Key Competitors 30
Neon Therapeutics Inc, Key Employees 31
List of Figures
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Neon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Neon Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer